Eisai and Clinilabs Drug Development Corporation conducted an analysis of Lemborexant (LEM) to determine its effectiveness as a treatment for insomnia. LEM is a competitive dual orexin-receptor antagonist that has been approved in multiple countries for the treatment of insomnia in adults. The analysis found that LEM helps improve sleep duration, daytime functioning, and fatigue in adults with insomnia, resulting in improved nighttime and daytime symptoms.
Click here to view the poster presented at SLEEP2024: Lemborexant Effect on Sleep Parameters in Adults With Moderate or Severe Chronic Obstructive Pulmonary Disease